Universität zu Köln

Herbrand, Amanda Katherina, Schmitt, Andreas M., Briel, Matthias ORCID: 0000-0002-2070-5230, Ewald, Hannah ORCID: 0000-0002-5081-1093, Goldkuhle, Marius, Diem, Stefan, Hoogkamer, Anouk, Joerger, Markus, Moffa, Giusi ORCID: 0000-0002-2739-0454, Novak, Urban, Hemkens, Lars G. and Kasenda, Benjamin ORCID: 0000-0003-0110-8585 (2021). Association of Supporting Trial Evidence and Reimbursement for Off-Label Use of Cancer Drugs. JAMA Netw. Open, 4 (3). CHICAGO: AMER MEDICAL ASSOC. ISSN 2574-3805

Full text not available from this repository.

Abstract

IMPORTANCE In many health systems, access to off-label drug use is controlled through reimbursement restrictions by health insurers, especially for expensive cancer drugs. OBJECTIVE To determine whether evidence from randomized clinical trials is associated with reimbursement decisions for requested off-label use of anticancer drugs in the Swiss health system. DESIGN, SETTING, AND PARTICIPANTS This cross-sectional study used reimbursement requests from routinely collected health records of 5809 patients with drug treatment for cancer between January 2015 and July 2018 in 3 major cancer centers, covering cancer care of approximately 5% of the Swiss population, to identify off-label drug use. For each off-label use indication with 3 or more requests, randomized clinical trial evidence on treatment benefits was systematically identified for overall survival (OS) or progression-free survival (PFS). Data were analyzed from August 2018 to December 2020. EXPOSURES Available randomized clinical trial evidence on benefits for OS or PFS for requested off-label use indications. MAIN OUTCOMES AND MEASURES The main outcome was the association between evidence for treatment benefit (expressed as improved OS or PFS) and reimbursement in multivariable regression models. RESULTS Among 3046 patients with cancer, 695 off-label use reimbursement requests in 303 different indications were made for 598 patients (median [interquartile range] age, 64 [53-73] years; 420 [60%] men). Off-label use was intended as first-line treatment in 311 requests (45%). Reimbursement was accepted in 446 requests (64%). For 71 indications, including 431 requests for 376 patients, there were 3 or more requests. Of these, 246 requests (57%) had no supporting evidence for OS or PFS benefit. Reimbursement was granted in 162 of 246 requests without supporting evidence (66%). Of 117 requests supported by OS benefit, 79 (67%) were reimbursed, and of 68 requests supported by PFS benefit alone, 54 (79%) were reimbursed. Evidence of OS benefit from randomized clinical trials was not associated with a higher chance of reimbursement (odds ratio, 0.76, 95% CI, 0.45-1.27). CONCLUSIONS AND RELEVANCE These findings suggest that in a health care system enabling access to off-label use, it was frequently intended as a first-line treatment in cancer care. Availability of randomized clinical trial evidence showing survival benefit was not associated with reimbursement decisions for off-label anticancer drug treatment in Switzerland. A transparent process with criteria considering clinical evidence is needed for evidence-based reimbursement decisions to ensure fair access to cancer treatments.

Item Type:	Journal Article
Creators:	Creators Email ORCID ORCID Put Code Herbrand, Amanda Katherina UNSPECIFIED UNSPECIFIED UNSPECIFIED Schmitt, Andreas M. UNSPECIFIED UNSPECIFIED UNSPECIFIED Briel, Matthias UNSPECIFIED orcid.org/0000-0002-2070-5230 UNSPECIFIED Ewald, Hannah UNSPECIFIED orcid.org/0000-0002-5081-1093 UNSPECIFIED Goldkuhle, Marius UNSPECIFIED UNSPECIFIED UNSPECIFIED Diem, Stefan UNSPECIFIED UNSPECIFIED UNSPECIFIED Hoogkamer, Anouk UNSPECIFIED UNSPECIFIED UNSPECIFIED Joerger, Markus UNSPECIFIED UNSPECIFIED UNSPECIFIED Moffa, Giusi UNSPECIFIED orcid.org/0000-0002-2739-0454 UNSPECIFIED Novak, Urban UNSPECIFIED UNSPECIFIED UNSPECIFIED Hemkens, Lars G. UNSPECIFIED UNSPECIFIED UNSPECIFIED Kasenda, Benjamin UNSPECIFIED orcid.org/0000-0003-0110-8585 UNSPECIFIED
URN:	urn:nbn:de:hbz:38-598704
DOI:	10.1001/jamanetworkopen.2021.0380
Journal or Publication Title:	JAMA Netw. Open
Volume:	4
Number:	3
Date:	2021
Publisher:	AMER MEDICAL ASSOC
Place of Publication:	CHICAGO
ISSN:	2574-3805
Language:	English
Faculty:	Unspecified
Divisions:	Unspecified
Subjects:	no entry
Uncontrolled Keywords:	Keywords Language ADJUVANT TREATMENT; COLON-CANCER; FLUOROURACIL; IRINOTECAN; LEUCOVORIN; ONCOLOGY Multiple languages Medicine, General & Internal Multiple languages
URI:	http://kups.ub.uni-koeln.de/id/eprint/59870